Article

Plasma and CSF proteomic signatures related to Alzheimer’s, α-synuclein, or vascular pathologies and clinical decline

2026-02-04

Abstract excerpt

Older individuals frequently harbor multiple brain pathologies, including Alzheimer’s disease (AD) related amyloid-β (Aβ) and tau alongside α-synucleinopathy and vascular pathology. Proteomic profiling offers a strategy to better understand common as well as unique features of these different brain pathologies. We analyzed cerebrospinal fluid (CSF) (n=1,658) and plasma (n=749) samples from participants in the BioF...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a03fbaa7-95dd-564c-a65f-02ab677f21ab
DOI: 10.64898/2026.02.04.26345534

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Plasma and CSF proteomic signatures related to Alzheimer’s, α-synuclein, or vascular pathologies and clinical declineDOI 10.64898/2026.02.04.26345534Read

Identification of Novel Biomarkers for Alzheimer’s Disease and Related Dementias Using Unbiased Plasma ProteomicsSemantic proximity Read

High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohortSemantic proximity Read

A genetic and proteomic comparison of key AD biomarkers across tissuesSemantic proximity Read

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s diseaseSemantic proximity Read

High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer's disease phenotypes in a large mixed-dementia cohort.Semantic proximity Read

Molecular Crossroads: Shared and Divergent Molecular Signatures in Alzheimer’s Disease and Dementia with Lewy BodiesSemantic proximity Read

Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s diseaseSemantic proximity Read

Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformSemantic proximity Read

Multi-cohort cerebrospinal fluid proteomics identifies robust molecular signatures across the Alzheimer disease continuumSemantic proximity Read

Proteomic profiling of Alzheimer’s disease and Vascular dementia reveals unique underlying signaturesSemantic proximity Read

Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profilesSemantic proximity Read

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profilesSemantic proximity Read